MTOR and tuberous sclerosis: Considering the evidence for mTOR inhibition not only rescuing neuronal, but also glial dysfunction, in preclinical TSC models (29, 255, 256), mTOR inhibitors, which were recently approved by the US Food and Drug Administration and European Medicines Agency for the treatment of refractory seizures associated to TSC starting from the age of 2 years (257), represent promising candidates to target TSC gliopathy.